Ogeda SA:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Ogeda SA - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C3468
◆発行会社(調査会社):GlobalData
◆発行日:2018年8月
◆ページ数:19
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:ベルギー
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Ogeda SA (Ogeda), formerly Euroscreen SA, a subsidiary of Astellas Pharma Inc, is a clinical-stage drug discovery company that invents and develops fezolinetant and small molecule drugs targeting G-protein coupled receptors. The company discovers and develops drugs that treat hormone-dependent pathologies in women’s health and drugs to treat neurodegenerative diseases and other exploratory programs for metabolic diseases such as diabetes and obesity. Ogeda offers G-protein-coupled receptors customized screening, cell lines and other services for biotech and pharmaceutical companies. The company conducts pre-clinical drug discovery programs in CNS, endocrine and inflammatory disorders. It partners with pharma companies to develop its products. Ogeda is headquartered in Gosselies, Belgium.

Ogeda SA – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Ogeda SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Ogeda SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Ogeda SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Ogeda SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Ogeda SA, Medical Devices Deals, 2012 to YTD 2018 9
Ogeda SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Ogeda SA, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
Euroscreen Raises USD17.8 Million in Series B Financing Round 11
Euroscreen Raises US$13 Million In Series A Financing 13
Licensing Agreements 14
Euroscreen Enters into Licensing Agreement with Merck 14
Acquisition 15
Astellas Pharma Acquires Ogeda for up to USD852 Million 15
Ogeda SA – Key Competitors 16
Ogeda SA – Key Employees 17
Ogeda SA – Locations And Subsidiaries 18
Head Office 18
Other Locations & Subsidiaries 18
Appendix 19
Methodology 19
About GlobalData 19
Contact Us 19
Disclaimer 19

List of Tables
Ogeda SA, Pharmaceuticals & Healthcare, Key Facts 2
Ogeda SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Ogeda SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Ogeda SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Ogeda SA, Deals By Therapy Area, 2012 to YTD 2018 8
Ogeda SA, Medical Devices Deals, 2012 to YTD 2018 9
Ogeda SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Euroscreen Raises USD17.8 Million in Series B Financing Round 11
Euroscreen Raises US$13 Million In Series A Financing 13
Euroscreen Enters into Licensing Agreement with Merck 14
Astellas Pharma Acquires Ogeda for up to USD852 Million 15
Ogeda SA, Key Competitors 16
Ogeda SA, Key Employees 17
Ogeda SA, Other Locations 18

List of Figures
Ogeda SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Ogeda SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Ogeda SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Ogeda SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Ogeda SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Ogeda SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Ogeda SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Ogeda SA, Medical Devices Deals, 2012 to YTD 2018 9

★海外企業調査レポート[Ogeda SA:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • XBiotech Inc (XBIT):企業の財務・戦略的SWOT分析
    Summary XBiotech Inc (XBiotech) is a biopharmaceutical company that discovers, develops and commercialize therapeutic antibodies based proprietary technology. The company offers monoclonal antibodies treatment for various diseases. It’s lead product Xilonix, a therapeutic antibody being developed fo …
  • Hester Biosciences Ltd (HESTERBIO):企業の財務・戦略的SWOT分析
    Hester Biosciences Ltd (HESTERBIO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • Lexicon Pharmaceuticals Inc (LXRX):企業の財務・戦略的SWOT分析
    Lexicon Pharmaceuticals Inc (LXRX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • Takuma Co Ltd (6013):企業の財務・戦略的SWOT分析
    Takuma Co Ltd (6013) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • IBIDEN CO., LTD.:企業の戦略・SWOT・財務情報
    IBIDEN CO., LTD. - Strategy, SWOT and Corporate Finance Report Summary IBIDEN CO., LTD. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Alucon Public Company Limited:戦略・SWOT・企業財務分析
    Alucon Public Company Limited - Strategy, SWOT and Corporate Finance Report Summary Alucon Public Company Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • Aareal Bank AG:企業の戦略・SWOT・財務情報
    Aareal Bank AG - Strategy, SWOT and Corporate Finance Report Summary Aareal Bank AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • Kasbah Resources Limited:戦略・SWOT・企業財務分析
    Kasbah Resources Limited - Strategy, SWOT and Corporate Finance Report Summary Kasbah Resources Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Bill Barrett Corp Oil & Gas Exploration and Production Operations and Cost Analysis – Q4, 2017
    Bill Barrett Corp Oil & Gas Exploration and Production Operations and Cost Analysis - Q4, 2017 Summary Bill Barrett Corp Oil & Gas Exploration and Production Operations and Cost Analysis is the latest report from GlobalData, the industry analysis specialists, that offers comprehensive information on …
  • Foundation for Innovative New Diagnostics-医療機器分野:企業M&A・提携分析
    Summary Foundation for Innovative New Diagnostics (FIND) is a non-profit organization that offers diagnostic tests. The organization develops and implements new diagnostic technologies for the development of diagnostic tests. Its services include diagnostic technologies development, quality-assured …
  • Biotronik SE & Co KG:企業の戦略的SWOT分析
    Biotronik SE & Co KG - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and s …
  • Sygnis AG (LIO1)-医療機器分野:企業M&A・提携分析
    Summary Sygnis AG (Sygnis), formerly Sygnis Pharma AG is a biopharmaceutical company that develops novel products and tools in fields of molecular biology. The company undertakes development and marketing of new molecular biological technologies for DNA amplification and sequencing. Its products inc …
  • Eldorado Gold Corporation:企業のM&A・事業提携・投資動向
    Eldorado Gold Corporation - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Eldorado Gold Corporation Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisi …
  • AXA Egypt:企業の戦略・SWOT・財務情報
    AXA Egypt - Strategy, SWOT and Corporate Finance Report Summary AXA Egypt - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions …
  • Nordion (Canada) Inc:企業の戦略的SWOT分析
    Nordion (Canada) Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and s …
  • Medimetriks Pharmaceuticals Inc-製薬・医療分野:企業M&A・提携分析
    Summary Medimetriks Pharmaceuticals Inc (MPI) is a drug company that offers skincare products. The company provides personal care products including cleansers, nutritional suppliments, cosmetic creams, and moisturizer. Its products include Centany, Ciclodan, Clindacin ETZ, Genadur, Ketodan, Morgidox …
  • Engineers India Limited (ENGINERSIN):企業の財務・戦略的SWOT分析
    Engineers India Limited (ENGINERSIN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Nabriva Therapeutics plc (NBRV):企業の財務・戦略的SWOT分析
    Summary Nabriva Therapeutics Plc (Nabriva) is a biopharmaceutical company that researches and develops antibiotics for the treatment of infections. The company offers product candidate such as Xenleta (lefamulin), CONTEPO (fosfomycin), being developed in both intravenous and oral formulations for th …
  • New Gold Inc
    New Gold Inc - Strategy, SWOT and Corporate Finance Report Summary New Gold Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Poupart Limited:企業の戦略・SWOT・財務分析
    Poupart Limited - Strategy, SWOT and Corporate Finance Report Summary Poupart Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆